Cancer risk in multiple sclerosis: Findings from British Columbia, Canada

Brain

Volumn 135, Issue 10, 2012, Pages 2973-2979

  Kingwell, Elaine ^a   Bajdik, Chris ^b   Phillips, Norm ^b   Zhu, Feng ^a   Oger, Joel ^a   Hashimoto, Stanley ^a   Tremlett, Helen ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Canada; cancer; diagnostic neglect; epidemiology; multiple sclerosis

Indexed keywords

ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SIZE; COHORT ANALYSIS; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LONGEVITY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIGRATION; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; RISK REDUCTION; STANDARDIZED INCIDENCE RATIO; TUMOR VOLUME; VITAL STATISTICS;

EID: 84867704011     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aws148     Document Type: Article

References (39)

1. Achiron A, Barak Y, Gail M, Mandel M, Pee D, Ayyagari R, et al. Cancer incidence in multiple sclerosis and effects of immunomodulatory treatments. Breast Cancer Res Treat 2005; 89: 265-70.
2. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol 2007; 61: 504-13.
3. Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T. Cancer risk among patients with multiple sclerosis and their parents. Neurology 2009; 72: 1170-7.
4. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004; 127(Pt 4): 844-50.
5. Cheng E, Myers L, Wolf S, Shatin D, Cui XP, Ellison G, et al. Mobility impairments and use of preventive services in women with multiple sclerosis: observational study. BMJ 2001; 323: 968-9.
6. Cools N, Ponsaerts P, Van Tendeloo VF, Berneman ZN. Regulatory T cells and human disease. Clin Dev Immunol 2007; 2007: 1-11.
7. Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, Lim HW, et al. Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch Dermatol 2011; 147: 1379-84.
8. Fois AF, Wotton CJ, Yeates D, Turner MR, Goldacre MJ. Cancer in patients with motor neuron disease, multiple sclerosis, and Parkinson's disease: record-linkage studies. J Neurol Neurosurg Psychiatry 2010; 81: 215-21.
9. Gallagher RP, Lee T. Assessing incidence rates and secular trends in nonmelanocytic skin cancer: which method is best? J Cutan Med Surg 1998; 3: 35-9.
10. Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P, Testori A. Vitamin D and skin cancer: a meta-analysis. Eur J Cancer 2009; 45: 634-41.
11. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J Epidemiol Community Health 2004; 58: 142-4.
12. Gonzalez EC, Ferrante JM, Van Durme DJ, Pal N, Roetzheim RG. Comorbid illness and the early detection of cancer. South Med J 2001; 94: 913-20.
13. Grytten Torkildsen N, Lie S, Aarseth J, Nyland H, Myhr K. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008; 14: 1191-8.
14. Hohlfeld R. Immunologic factors in primary progressive multiple sclerosis. Mult Scler 2004; 10 (Suppl 1): S16-21; discussion S-2.
15. Jensen AO, Thomsen HF, Engebjerg MC, Olesen AB, Friis S, Karagas MR, et al. Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: a population-based case-control study. Br J Cancer 2009; 100: 200-5.
16. Jutte DP, Roos LL, Brownell MD. Administrative record linkage as a tool for public health research. Annu Rev Public Health 2011; 32: 91-108.
17. Karagas MR, Cushing GL Jr, Greenberg ER, Mott LA, Spencer SK, Nierenberg DW. Non-melanoma skin cancers and glucocorticoid therapy. Br J Cancer 2001; 85: 683-6.
18. Landgren AM, Landgren O, Gridley G, Dores GM, Linet MS, Morton LM. Autoimmune disease and subsequent risk of developing alimentary tract cancers among 4.5 million US male veterans. Cancer 2011; 117: 1163-71.
19. Lebrun C, Debouverie M, Vermersch P, Clavelou P, Rumbach L, de Seze J, et al. Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis. Mult Scler 2008; 14: 399-405.
20. Lebrun C, Vermersch P, Brassat D, Defer G, Rumbach L, Clavelou P, et al. Cancer and multiple sclerosis in the era of disease-modifying treatments. J Neurol 2011; 258: 1304-11.
21. Leong EM, Semple SJ, Angley M, Siebert W, Petkov J, McKinnon RA. Complementary and alternative medicines and dietary interventions in multiple sclerosis: what is being used in South Australia and why? Complement Ther Med 2009; 17: 216-23.
22. Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. High frequency of adverse health behaviors in multiple sclerosis. Mult Scler 2009; 15: 105-13.
23. Midgard R, Glattre E, Gronning M, Riise T, Edland A, Nyland H. Multiple sclerosis and cancer in Norway. A retrospective cohort study. Acta NeurolScand 1996; 93: 411-5.
24. Moller H, Kneller RW, Boice JD Jr, Olsen JH. Cancer incidence following hospitalization for multiple sclerosis in Denmark. Acta NeurolScand 1991; 84: 214-20.
25. Nielsen NM, Rostgaard K, Rasmussen S, Koch-Henriksen N, Storm HH, Melbye M, et al. Cancer risk among patients with multiple sclerosis: a population-based register study. Int J Cancer 2006; 118: 979-84.
26. Nortvedt MW, Riise T, Maeland JG. Multiple sclerosis and lifestyle factors: the Hordaland Health Study. Neurol Sci 2005; 26: 334-9.
27. Nosek MA, Howland CA. Breast and cervical cancer screening among women with physical disabilities. Arch Phys Med Rehab 1997; 78: S39-44.
28. Pohar SL, Jones CA, Warren S, Turpin KV, Warren K. Health status and health care utilization of multiple sclerosis in Canada. Can J Neurol Sci 2007; 34: 167-74.
29. Roos LL, Nicol JP. A research registry: uses, development, and accuracy. J Clin Epidemiol 1999; 52: 39-47.
30. Sadovnick AD, Eisen K, Ebers GC, Paty DW. Cause of death in patients attending multiple sclerosis clinics. Neurology 1991; 41: 1193-6.
31. Smestad C, Sandvik L, Celius EG. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. Mult Scler 2009; 15: 1263-70.
32. Sobin LH, Gospodarowicz MK, Wittekind C. TNM Classification of malignant tumours. 7th edn. Oxford: John Wiley & Sons Ltd.; 2009.
33. Sorensen HT, Mellemkjaer L, Nielsen GL, Baron JA, Olsen JH, Karagas MR. Skin cancers and non-hodgkin lymphoma among users of systemic glucocorticoids: a population-based cohort study. J Natl Cancer Inst 2004; 96: 709-11.
34. Sumelahti ML, Pukkala E, Hakama M. Cancer incidence in multiple sclerosis: a 35-year follow-up. Neuroepidemiology 2004; 23: 224-7.
35. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. J Clin Oncol 2011; 29: 3078-84.
36. Terret C, Castel-Kremer E, Albrand G, Droz JP. Effects of comorbidity on screening and early diagnosis of cancer in elderly people. Lancet Oncol 2009; 10: 80-7.
37. Tremlett H, Zhao Y, Rieckmann P, Hutchinson M. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74: 2004-15.
38. World Health Organization and Multiple Sclerosis International Federation. Atlas: Multiple Sclerosis Resources in the World 2008. WHO Library Cataloguing-in-Publication Data; 2009. Available from: http://www.who.int/ mental-health/neurology/Atlas-MS-WEB.pdf (23 August 2011, last date accessed).
39. Zozulya AL, Wiendl H. The role of regulatory T cells in multiple sclerosis. Nat Clin Pract Neurol 2008; 4: 384-98.